ClinicalTrials.gg
RecruitingNCT07398300Updated Oct 27, 2026

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

An interventional study of GIP and GLP-1 in Type 2 Diabetes and Healhty, sponsored by Copenhagen University Hospital, Rigshospitalet. Recruiting at 1 site in Denmark. Open to participants aged 23 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 27, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
23 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Glucagon-Like Peptide 1 · Diabetes Mellitus, Type 2.

Planned enrollment
3rd of 11
36 · median 20
Started
2026
the only one that year
No phase
7 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Copenhagen University Hospital, Rigshospitalet

Among the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 is open now, in 1 country.

By country, each count listing its studies:

About Glucagon-Like Peptide 1

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 23 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion.

The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning.

Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion.

The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.

03

Conditions studied

  • Type 2 Diabetes
  • Healhty

Keywords

  • IncretinPET
04

Who can participate

Ages eligible
23 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Sub-study 1 (Healthy individuals):

  • Age 23-50 years
  • 20.0-26.9 kg/m²
  • \< 42 mmol/mol
  • Able to provide

Sub-study 2 - Participants with Type 2 Diabetes:

  • Age 23-60 years
  • Diagnosed with type 2 diabetes for ≥3 months
  • HbA1c > 53 mmol/mol
  • Treatment with metformin only
  • Able to provide informed consent

Sub-study 2 - Healthy control participants:

  • Age 23-64 years
  • HbA1c \< 42 mmol/mol
  • Able to provide informed consent

Exclusion Criteria (applies to all participants unless otherwise specified):

  • Anaemia ( below normal range)
  • > 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder
  • Kidney disease (creatinine above normal range)
  • Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)
  • For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol
  • Use of glucose-lowering medications other than metformin (Sub-study 2 only)
  • (Sub-study 2 only)
  • Regular tobacco smoking or use of nicotine-containing products
  • Claustrophobia
  • Pregnancy, breastfeeding, or intention to become pregnant during the study period
  • Initiation of special diets, major lifestyle changes, or weight loss > 5% within 3 months prior to or during the study
  • Any medication or physical/psychological condition that may interfere with participation (per investigator judgement)
  • Inability to speak or read Danish
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    GIP infusion

    Drug: GIP

  • Experimental
    GLP-1 infusion

    Drug: GLP-1

  • Experimental
    Saline Placebo

    Other: Saline (0.9% Sodium Chloride)

Interventions

  • DrugGastric Inhibitory PolypeptideStudies of Gastric Inhibitory PolypeptideGastric Inhibitory Polypeptide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of 6 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology

  • DrugGlucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology.

  • OtherSaline (0.9% Sodium Chloride)

    Intravenous infusion of isotonic saline administered as placebo. In sub-study 1, saline serves as a control condition; in sub-study 2, saline is infused for 15 minutes prior to hormone infusion.

06

What researchers measure

Primary outcomes

  1. Metabolic Rate of FDG

    MRFDG quantified using dynamic total-body 18F-FDG PET with 3-compartment kinetic modelling during infusion of GIP, GLP-1, or placebo.

    Time frame: 75 minuts

Secondary outcomes

  1. Perfusion of skeletal muscle

    Time frame: 75 min

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 12 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 9, 2026
StartActual
Mar 12, 2026
Primary completionEst.
Mar 12, 2027
CompletionEst.
May 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Sponsor Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
    + 2 other changes: identifiers and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07398300
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Mathilde Borring Brogaard (Doctor, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Feb 9, 2026
Start date
Mar 12, 2026
Primary completion
Mar 12, 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Mathilde Borring Brogaard, Doctor
Contact
mathilde.borring.brogaard@regionh.dk
+4535454498
Per Cramon, Doctor
Contact
Per.Cramon@regionh.dk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gastric Inhibitory Polypeptide · Glucagon-Like Peptide 1

Start the discussion